Coeptis Therapeutics Holdings Inc. Common Stock
COEPStock
$7.20−45.29%52W
Market Cap$102.06M
P/E—
Div yield—
Beta0.35
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-59.96%
Price vs S&P 500 (4W)-31.70%
VGM Score14.71
Market Capitalization$102.06M
Analyst Recommendations
Nov 2024
Dec 2024
Jan 2025
Feb 2025
2.17
2.17
2.17
2.17
Industry Peers — Finance Services(161)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
COEPCoeptis Therapeutics Holdings Inc. Common Stock | F | — | D | $7.20 |
| AXPAmerican Express Company | D | B | B | $361.57 |
| NUNu Holdings Ltd. | D | B | C | $13.79 |
| COINCoinbase Global, Inc. Class A Common Stock | D | C | C | $160.49 |
| MSTRStrategy Inc Common Stock Class A | D | D | D | $94.03 |
| SYFSYNCHRONY FINANCIAL | B | C | B | $74.28 |
| SOFISoFi Technologies, Inc. Common Stock | D | B | C | $17.32 |
| CRCLCircle Internet Group, Inc. | D | C | D | $60.64 |
| IRENIREN Limited Ordinary Shares | F | B | B | $34.83 |
| HUTHut 8 Corp. Common Stock | F | B | A | $91.91 |
| WULFTeraWulf Inc. Common Stock | F | B | B | $17.98 |
About
Coeptis Therapeutics develops cell therapy platforms for cancer patients. The company's pipeline includes SNAP-CAR, a multi-antigen CAR T technology licensed from the University of Pittsburgh, and CD38-GEAR-NK, a cell therapy candidate, along with a companion diagnostic. Coeptis collaborates with VyGen-Bio and the Karolinska Institutet on its CD38-targeted oncology programs.